LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 166

Search options

  1. Article ; Online: The aberrant glycolysis in kidney proximal tubule: potential therapeutic target for DKD.

    Kanasaki, Keizo

    Kidney international

    2023  Volume 104, Issue 6, Page(s) 1056–1059

    Abstract: The presence of glycolysis in kidney proximal tubule has been long debated. However, recent reports suggest that aberrant glycolysis is induced in pathologic conditions and may play a critical role in kidney damage. Azushima et al. provided additional ... ...

    Abstract The presence of glycolysis in kidney proximal tubule has been long debated. However, recent reports suggest that aberrant glycolysis is induced in pathologic conditions and may play a critical role in kidney damage. Azushima et al. provided additional evidence that the accumulation of glycolysis-derived lactate could be the clue to understanding the pathogenesis of diabetic kidney disease.
    MeSH term(s) Kidney Tubules ; Kidney ; Kidney Tubules, Proximal ; Glycolysis ; Lactic Acid
    Chemical Substances Lactic Acid (33X04XA5AT)
    Language English
    Publishing date 2023-11-18
    Publishing country United States
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Comment
    ZDB-ID 120573-0
    ISSN 1523-1755 ; 0085-2538
    ISSN (online) 1523-1755
    ISSN 0085-2538
    DOI 10.1016/j.kint.2023.09.019
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 797: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article ; Online: Nutrient-derived modification of mineral corticoid receptors is relevant to diabetic kidney disease progression.

    Kanasaki, Keizo

    Hypertension research : official journal of the Japanese Society of Hypertension

    2022  Volume 46, Issue 1, Page(s) 261–263

    MeSH term(s) Humans ; Diabetic Nephropathies ; Receptors, Mineralocorticoid ; Carrier Proteins ; Hypertension ; Nutrients ; Minerals ; Adrenal Cortex Hormones ; Diabetes Mellitus
    Chemical Substances Receptors, Mineralocorticoid ; Carrier Proteins ; Minerals ; Adrenal Cortex Hormones
    Language English
    Publishing date 2022-11-15
    Publishing country England
    Document type Editorial ; Comment
    ZDB-ID 1175297-x
    ISSN 1348-4214 ; 0916-9636
    ISSN (online) 1348-4214
    ISSN 0916-9636
    DOI 10.1038/s41440-022-01107-8
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 3898: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Article ; Online: Cancer biology in diabetes update: Focusing on antidiabetic drugs.

    Kawakita, Emi / Kanasaki, Keizo

    Journal of diabetes investigation

    2024  Volume 15, Issue 5, Page(s) 525–540

    Abstract: The association of type 2 diabetes with certain cancer risk has been of great interest for years. However, the effect of diabetic medications on cancer development is not fully understood. Prospective clinical trials have not elucidated the long-term ... ...

    Abstract The association of type 2 diabetes with certain cancer risk has been of great interest for years. However, the effect of diabetic medications on cancer development is not fully understood. Prospective clinical trials have not elucidated the long-term influence of hypoglycemic drugs on cancer incidence and the safety for cancer-bearing patients with diabetes, whereas numerous preclinical studies have shown that antidiabetic drugs could have an impact on carcinogenesis processes beyond the glycemic control effect. Because there is no evidence of the safety profile of antidiabetic agents on cancer biology, careful consideration would be required when prescribing any medicines to patients with diabetes and existing tumor. In this review, we discuss the potential influence of each diabetes therapy in cancer 'initiation', 'promotion' and 'progression'.
    MeSH term(s) Humans ; Hypoglycemic Agents/therapeutic use ; Neoplasms/drug therapy ; Diabetes Mellitus, Type 2/drug therapy ; Animals
    Chemical Substances Hypoglycemic Agents
    Language English
    Publishing date 2024-03-08
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 2625840-7
    ISSN 2040-1124 ; 2040-1116
    ISSN (online) 2040-1124
    ISSN 2040-1116
    DOI 10.1111/jdi.14152
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6920: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  4. Article ; Online: N-acetyl-seryl-aspartyl-lysyl-proline is a valuable endogenous antifibrotic peptide for kidney fibrosis in diabetes: An update and translational aspects.

    Kanasaki, Keizo

    Journal of diabetes investigation

    2020  Volume 11, Issue 3, Page(s) 516–526

    Abstract: N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous peptide that has been confirmed to show excellent organ-protective effects. Even though originally discovered as a modulator of hemotopoietic stem cells, during the recent two decades, ... ...

    Abstract N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an endogenous peptide that has been confirmed to show excellent organ-protective effects. Even though originally discovered as a modulator of hemotopoietic stem cells, during the recent two decades, AcSDKP has been recognized as valuable antifibrotic peptide. The antifibrotic mechanism of AcSDKP is not yet clear; we have established that AcSDKP could target endothelial-mesenchymal transition program through the induction of the endothelial fibroblast growth factor receptor signaling pathway. Also, recent reports suggested the clinical significance of AcSDKP. The aim of this review was to update recent advances of the mechanistic action of AcSDKP and discuss translational research aspects.
    MeSH term(s) Animals ; Diabetes Complications/metabolism ; Fibrosis/metabolism ; Humans ; Kidney/metabolism ; Kidney/pathology ; Kidney Diseases/etiology ; Kidney Diseases/metabolism ; Kidney Diseases/pathology ; Oligopeptides/metabolism ; Peptidyl-Dipeptidase A/metabolism ; Signal Transduction
    Chemical Substances Oligopeptides ; Peptidyl-Dipeptidase A (EC 3.4.15.1) ; goralatide (H041538E9P)
    Language English
    Publishing date 2020-03-11
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 2625840-7
    ISSN 2040-1124 ; 2040-1116
    ISSN (online) 2040-1124
    ISSN 2040-1116
    DOI 10.1111/jdi.13219
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6920: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article: Editorial: Receptor biology and cell signaling in diabetes: volume II.

    Srivastava, Swayam Prakash / Kanasaki, Keizo

    Frontiers in pharmacology

    2023  Volume 14, Page(s) 1274914

    Language English
    Publishing date 2023-09-13
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2023.1274914
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Article ; Online: Epigenetic regulation of core genes linking to diabetic nephropathy progression: Lesson from FinnDiane type 1 diabetes study.

    Makino, Hirofumi / Kanasaki, Keizo

    Journal of diabetes investigation

    2023  Volume 14, Issue 12, Page(s) 1341–1343

    MeSH term(s) Humans ; Diabetic Nephropathies/genetics ; Diabetes Mellitus, Type 1/complications ; Diabetes Mellitus, Type 1/genetics ; Epigenesis, Genetic ; Diabetic Retinopathy/genetics ; Disease Progression
    Language English
    Publishing date 2023-09-29
    Publishing country Japan
    Document type Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 2625840-7
    ISSN 2040-1124 ; 2040-1116
    ISSN (online) 2040-1124
    ISSN 2040-1116
    DOI 10.1111/jdi.14083
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6920: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  7. Article ; Online: Correction: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

    Kanasaki, Keizo

    Clinical science (London, England : 1979)

    2019  Volume 133, Issue 1, Page(s) 151

    Language English
    Publishing date 2019-01-15
    Publishing country England
    Document type Journal Article ; Published Erratum
    ZDB-ID 206835-7
    ISSN 1470-8736 ; 0301-0538 ; 0009-0360 ; 0143-5221
    ISSN (online) 1470-8736
    ISSN 0301-0538 ; 0009-0360 ; 0143-5221
    DOI 10.1042/CS20180031_COR
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.220: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article ; Online: The role of renal dipeptidyl peptidase-4 in kidney disease: renal effects of dipeptidyl peptidase-4 inhibitors with a focus on linagliptin.

    Kanasaki, Keizo

    Clinical science (London, England : 1979)

    2018  Volume 132, Issue 4, Page(s) 489–507

    Abstract: Emerging evidence suggests that dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes may have nephroprotective effects beyond the reduced renal risk conferred by glycemic control. DPP-4 is a ubiquitous protein with exopeptidase ... ...

    Abstract Emerging evidence suggests that dipeptidyl peptidase-4 (DPP-4) inhibitors used to treat type 2 diabetes may have nephroprotective effects beyond the reduced renal risk conferred by glycemic control. DPP-4 is a ubiquitous protein with exopeptidase activity that exists in cell membrane-bound and soluble forms. The kidneys contain the highest levels of DPP-4, which is increased in diabetic nephropathy. DPP-4 inhibitors are a chemically heterogeneous class of drugs with important pharmacological differences. Of the globally marketed DPP-4 inhibitors, linagliptin is of particular interest for diabetic nephropathy as it is the only compound that is not predominantly excreted in the urine. Linagliptin is also the most potent DPP-4 inhibitor, has the highest affinity for this protein, and has the largest volume of distribution; these properties allow linagliptin to penetrate kidney tissue and tightly bind resident DPP-4. In animal models of kidney disease, linagliptin elicited multiple renoprotective effects, including reducing albuminuria, glomerulosclerosis, and tubulointerstitial fibrosis, independent of changes in glucagon-like peptide-1 (GLP-1) and glucose levels. At the molecular level, linagliptin prevented the pro-fibrotic endothelial-to-mesenchymal transition by disrupting the interaction between membrane-bound DPP-4 and integrin β1 that enhances signaling by transforming growth factor-β1 and vascular endothelial growth factor receptor-1. Linagliptin also increased stromal cell derived factor-1 levels, ameliorated endothelial dysfunction, and displayed unique antioxidant effects. Although the nephroprotective effects of linagliptin are yet to be translated to the clinical setting, the ongoing Cardiovascular and Renal Microvascular Outcome Study with Linagliptin in Patients with Type 2 Diabetes Mellitus (CARMELINA®) study will definitively assess the renal effects of this DPP-4 inhibitor. CARMELINA® is the only clinical trial of a DPP-4 inhibitor powered to evaluate kidney outcomes.
    MeSH term(s) Animals ; Diabetes Mellitus, Type 2/complications ; Diabetes Mellitus, Type 2/drug therapy ; Diabetic Nephropathies/drug therapy ; Dipeptidyl Peptidase 4/drug effects ; Dipeptidyl-Peptidase IV Inhibitors/pharmacology ; Humans ; Hypoglycemic Agents/pharmacology ; Linagliptin/pharmacology
    Chemical Substances Dipeptidyl-Peptidase IV Inhibitors ; Hypoglycemic Agents ; Linagliptin (3X29ZEJ4R2) ; Dipeptidyl Peptidase 4 (EC 3.4.14.5)
    Keywords covid19
    Language English
    Publishing date 2018-02-28
    Publishing country England
    Document type Journal Article ; Research Support, Non-U.S. Gov't ; Review
    ZDB-ID 206835-7
    ISSN 1470-8736 ; 0301-0538 ; 0009-0360 ; 0143-5221
    ISSN (online) 1470-8736
    ISSN 0301-0538 ; 0009-0360 ; 0143-5221
    DOI 10.1042/CS20180031
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Ua VI Zs.220: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: Editorial: Receptor Biology and Cell Signaling in Diabetes.

    Srivastava, Swayam Prakash / Kanasaki, Keizo

    Frontiers in pharmacology

    2022  Volume 13, Page(s) 864117

    Language English
    Publishing date 2022-03-16
    Publishing country Switzerland
    Document type Editorial
    ZDB-ID 2587355-6
    ISSN 1663-9812
    ISSN 1663-9812
    DOI 10.3389/fphar.2022.864117
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article ; Online: Tumor progression with thyrotoxicosis on differentiated thyroid carcinoma due to thyrotropin receptor stimulation: is tyrosine kinase inhibitors the cause of thyroid stimulating hormone receptor antibody positivity?

    Notsu, Masakazu / Kanasaki, Keizo

    Annals of palliative medicine

    2022  Volume 11, Issue 9, Page(s) 2806–2809

    MeSH term(s) Disease Progression ; Humans ; Protein Kinase Inhibitors/adverse effects ; Receptors, Thyrotropin ; Thyroid Neoplasms/complications ; Thyrotoxicosis/chemically induced ; Thyrotropin
    Chemical Substances Protein Kinase Inhibitors ; Receptors, Thyrotropin ; Thyrotropin (9002-71-5)
    Language English
    Publishing date 2022-10-10
    Publishing country China
    Document type Editorial
    ZDB-ID 2828544-X
    ISSN 2224-5839 ; 2224-5839
    ISSN (online) 2224-5839
    ISSN 2224-5839
    DOI 10.21037/apm-22-971
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top